How to Choose Which Biotech Conferences to Sponsor in 2027: A 10-Point Scorecard

How to Choose Which Biotech Conferences to Sponsor in 2027: A 10-Point Scorecard

Most diagnostics, tools, CRO and platform companies set their event budget the same way every year: renew last year’s shows, add one that a competitor attended, and drop whichever one produced the least memorable booth traffic. The result is a calendar built on habit rather than evidence.

If you are working out how to choose a trade show or conference to sponsor in 2027, a simple, repeatable scoring method will do more for your pipeline than any single event. This guide gives you a 10-point scorecard you can apply to every option on your shortlist, from a 20,000-person oncology congress to a 300-person focused summit, along with the questions to ask organisers before you sign, the red flags to watch for, and a worked example.

Key takeaways

• Score every event on the same 10 criteria, each rated 1–5, then weight the criteria that matter most for your goal.
• Audience fit to your ideal customer profile (ICP) is the one criterion that can veto an event on its own.
• Cost per qualified conversation is a better comparison metric than cost per lead or total attendance.
• Large congresses usually win on reach, scientific visibility and launch moments. Focused summits usually win on seniority, meeting density and lower competitor clutter.
• Ask organisers for attendee data, meeting mechanics and post-event reporting in writing before you commit.

Why a scorecard beats gut feel

Event sponsorship is usually one of the largest discretionary lines in a life sciences marketing budget, and it is also one of the hardest to defend after the fact. A scorecard does three useful things. It forces you to define what a good event looks like for your company before the sales pitch starts. It lets you compare very different formats on the same terms. And it gives finance and leadership a clear, documented rationale for every yes and every no.

The research on what attendees value supports this kind of discipline. In Freeman’s 2025 commercial trends research, 84% of respondents said conversations with subject matter experts are crucial, and commerce ranked as the most valued part of an event, ahead of experience, learning and networking (Freeman, 2025). A separate Freeman report found that more than a third of attendees say networking must feel curated to be effective, and nearly half of younger professionals want curated recommendations for who to meet before the event (Freeman, 2025). In other words, the events that work are the ones that put the right people in front of each other on purpose.

The 10-point conference sponsorship scorecard

Rate each event from 1 (poor) to 5 (excellent) on every criterion. Use the descriptors below so that different people on your team score consistently.

Notes on scoring the trickier criteria

Audience fit. Write your ICP down first: account types (for example, mid-size biotech with an oncology pipeline, top-20 pharma translational teams), functions (translational medicine, biomarker strategy, clinical operations, BD) and seniority. Then score each event against that list, not against a general sense of “the right crowd”.

Cost per qualified conversation. Add every cost: the package, booth build or shipping, travel, accommodation and the working days your team spends away. Divide by a realistic estimate of conversations with people who match your ICP and could move an opportunity forward. Compare events relative to one another rather than against an absolute benchmark. If you want a structured way to model this, the ImmunoMark sponsorship ROI calculator lets you plug in your own assumptions, and our guide to measuring trade show ROI covers the method in more detail.

Timing. For companion diagnostic and assay partners, the useful window is often before a sponsor’s clinical programme locks its biomarker strategy. Our guide to CDx co-development explains why diagnostics partners need to be in the conversation early.

How to weight the scorecard and read the totals

Not every criterion matters equally for every goal. Apply a weight of ×1, ×2 or ×3 to each one. As a starting point for a BD-led sponsorship aimed at new partnerships, we suggest:

With these weights the maximum possible score is 75 (15 weight points × 5). A practical way to read the totals:

• 60–75: commit. A strong fit. Sponsor, and plan pre-event outreach to make the most of it.
• 45–59: conditional. Worth doing if you can fix the weak criteria, for example by negotiating meetings, a speaking slot or better data.
• Below 45: attend or skip. Send one or two people as delegates, or put the budget elsewhere.

Add one rule on top: if an event scores 1 on audience fit, it is out, whatever the total. If your goal is brand awareness or a product launch rather than partnering, move the extra weight from 1:1 meetings to content relevance and speaking access, and re-score.

Want a ready-made version? Ask our team for the scorecard as a spreadsheet, with the weights and formulas already set up.

Big congress or focused summit? The trade-offs

The most common decision on a 2027 shortlist is not between two similar events. It is between a booth at a large international congress with 20,000 or more attendees and a sponsorship at a focused summit of around 300 people. Both can be the right answer.

Where a large congress wins

• Reach and visibility. If you need to be seen by the whole field, including clinicians and academic groups, nothing else matches it.
• Launch moments. Major data presentations and product launches often belong where the scientific community and press are already gathered.
• Breadth of accounts. You can meet many companies and institutions in one trip, including ones you did not know to target.
• Expectation. For market leaders, absence can be noticed.

Where a focused summit wins

• Seniority and density. A higher share of attendees are budget holders in your niche, and they are easier to find.
• Meetings. Organiser-arranged 1:1s are common, so you leave with a list of named conversations rather than badge scans.
• Less clutter. Fewer sponsors means less competition for attention and fewer direct competitors in the room.
• Speaking access. Sponsors can often contribute a case study or panel seat in the main programme.

Many diagnostics and tools companies end up with a mix: one or two large congresses for presence and launches, plus a small number of focused meetings for pipeline. The scorecard tells you which events earn each role.

Worked example: congress booth vs focused summit

Imagine a mid-size multiplex assay company whose ICP is translational and biomarker leads at oncology biotech and pharma, and whose 2027 goal is new pharma service partnerships. It is comparing a standard booth at a large oncology congress with a mid-tier sponsorship at a focused immuno-oncology and biomarker summit. Using the BD weights above:

For this company and this goal, the focused summit is the clear commit and the congress falls into “attend, do not exhibit”. The team might still send two scientists to the congress to follow the data and hold self-booked meetings.

Now change the goal. If the same company were launching a new panel with a clinical validation dataset and wanted maximum field awareness, re-weighting towards content relevance, speaking and reach would close much of the gap, and a congress presence (perhaps a poster plus a modest booth) could be justified. The point of the scorecard is not to make focused events win. It is to make the reasoning visible.

Questions to ask organisers before you sign

• What was the attendee breakdown by sector, function and seniority at the last edition, and is it from a post-show report or a forecast?
• Can you share a list of companies that attended last time?
• How are 1:1 meetings arranged? Who chooses, who confirms, and what is the typical number per sponsor at my level?
• How many sponsors and exhibitors will there be, and will any direct competitors be at the same level?
• Is there a speaking opportunity in the main programme, and who approves the content?
• What data will I receive after the event, in what format, and on what consent basis?
• What happens if attendance falls well short of the forecast?

Red flags

• Only a headline number. “5,000 attendees” with no breakdown by job level or sector.
• Vague meeting promises. “Unlimited networking” with no mechanism or typical meeting count.
• An audience full of vendors. If sponsors and exhibitors make up a large share of the room, your buyers are outnumbered.
• No past company list or post-show report for an event that has run before.
• Pressure to sign quickly without answers to the questions above.
• Badge scans as the only deliverable. A scan is not a conversation, and it rarely survives follow-up.

How ImmunoMark Summit scores, honestly

We built ImmunoMark Summit around the criteria in this scorecard, so it is fair to say where it does well and where it does not.

It tends to score highly on pre-arranged 1:1 meetings, seniority and audience fit for companies selling into immuno-oncology and biomarker teams. At London 2026, 70% of attendees were senior decision-makers, sponsors typically held 15–25 meetings each, and title sponsors had 55+ pre-scheduled 1:1s. The programme runs two streams, Next-Gen Immuno-Oncology and Biomarkers & Companion Diagnostics, so content relevance is high if your product touches IO biomarker strategy or the companion diagnostic pathway.

It will not give you the reach of a large international congress. If your goal is to be seen by thousands of clinicians, or to launch alongside a major data presentation, a big congress is the better choice, and we would tell you so. To see where we fit among the wider calendar, our list of the best immuno-oncology conferences to attend covers both large and focused meetings.

Sponsoring ImmunoMark Summit in 2027

ImmunoMark Summit runs three editions in 2027: the immuno-oncology conference in San Diego (10–11 February 2027, 300+ senior attendees), the immuno-oncology and biomarker conference in London (3–4 March 2027, 400+ expected) and the immuno-oncology conference in Boston (June 2027, 300+ attendees). Each combines keynotes, panels, case studies, pre-arranged 1:1 meetings and a Day 1 drinks reception.

Run the numbers for your own team with the sponsorship ROI calculator, then score us against your shortlist.

Explore ImmunoMark 2027 sponsorship

If your company wants to meet this audience, see the Boston 2027 sponsorship opportunities, or the packages for San Diego and London.

FAQs

How do you choose a trade show or conference to sponsor?

Score each option on the same criteria: audience fit to your ideal customer profile, seniority, attendee data transparency, pre-arranged 1:1 meetings, competitor clutter, speaking access, content relevance, timing, cost per qualified conversation and post-event data. Weight the criteria that matter most for your goal and compare the totals.

Is it better to sponsor a large congress or a focused summit?

It depends on your goal. Large congresses are better for reach, scientific visibility and product launches. Focused summits are usually better for senior audiences, pre-arranged meetings and a lower cost per qualified conversation. Many companies use both for different roles.

What is a good way to measure conference sponsorship ROI?

Cost per qualified conversation is a practical starting metric: divide the full cost of the event, including travel and staff time, by the number of conversations with people who match your ideal customer profile. Then track how many of those conversations become opportunities over the following months.

What should I ask an event organiser before sponsoring?

Ask for the attendee breakdown by sector and seniority from a past edition, a list of companies that attended, how 1:1 meetings are arranged and how many meetings sponsors typically get, how many competitors will be present, and what data you will receive after the event.